Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 SARS-CoV-2 Infection Clear all
Terminated Phase 3 Interventional

Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis

NCT04707703
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2, Aspergillosis Invasive
Interventions
Isavuconazonium Injection [Cresemba], Placebo
Drug
Lead sponsor
Jeffrey Jenks, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Orange, California • Sacramento, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 14, 2026, 9:04 AM EDT
Terminated Not applicable Interventional

Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device

NCT04595903
View directory record Official record
Conditions
COVID-19
Interventions
Hemopurifier
Device
Lead sponsor
Aethlon Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
9
States / cities
Irvine, California • Loma Linda, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 14, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

Niclosamide for Mild to Moderate COVID-19

NCT04399356
View directory record Official record
Conditions
COVID-19
Interventions
Niclosamide, Placebo, Telehealth monitoring
Drug · Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 14, 2026, 9:04 AM EDT
Terminated Early Phase 1 Interventional

Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19

NCT04703036
View directory record Official record
Conditions
Covid19
Interventions
Glycine, N-acetylcysteine, Alanine
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
55 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 14, 2026, 9:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mindfulness During COVID-19

NCT04319445
View directory record Official record
Conditions
Migraine Disorders, Stress, Anxiety
Interventions
Mindfulness session(s)
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 14, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

Pre-exposure Prophylaxis for SARS-Coronavirus-2

NCT04328467
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, ARDS, Acute Respiratory Distress Syndrome
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 14, 2026, 9:04 AM EDT
Completed Not applicable Interventional

The COPE Study: Pilot Intervention to Improve Symptom Self-management and Coping in Adults With Post COVID-19

NCT05658536
View directory record Official record
Conditions
Post COVID-19 Condition, Post-COVID-19 Syndrome
Interventions
6-Week Self-Management Group
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 14, 2026, 9:04 AM EDT
Terminated Phase 2 Interventional

Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19

NCT04373044
View directory record Official record
Conditions
Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Baricitinib, Hydroxychloroquine, Placebo Administration
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 14, 2026, 9:04 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

NCT04798001
View directory record Official record
Conditions
Covid19
Interventions
Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray
Biological
Lead sponsor
Meissa Vaccines, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Lenexa, Kansas • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 14, 2026, 9:04 AM EDT
No Longer Available No phase listed Expanded access

Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04445207
View directory record Official record
Conditions
COVID, Sars-CoV2, Corona Virus Infection
Interventions
Convalescent Plasma
Biological
Lead sponsor
Jonathan Gerber
Other
Eligibility
12 Years and older
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 14, 2026, 9:04 AM EDT
Terminated Phase 1Phase 2 Interventional

The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin

NCT04601077
View directory record Official record
Conditions
COVID-19
Interventions
Nitric Oxide lozenges, 30 mg, Placebo
Drug
Lead sponsor
Nitric Oxide Innovations LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lake Bluff, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 14, 2026, 9:04 AM EDT
Terminated No phase listed Observational

COVID-19 (Coronavirus Disease-2019) Psychiatric Outcomes

NCT05119400
View directory record Official record
Conditions
Covid19, Anxiety, Mood, Cognitive Impairment
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 14, 2026, 9:04 AM EDT
Completed No phase listed Observational

WGS Analysis of COVID-19 Positive Patients

NCT04353401
View directory record Official record
Conditions
Coronavirus Infection, COVID-19
Interventions
Not listed
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 14, 2026, 9:04 AM EDT
Withdrawn Phase 1Phase 2 Interventional

ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)

NCT05433181
View directory record Official record
Conditions
SARS-CoV-2
Interventions
ACE2 Chewing Gum, Placebo Chewing Gum
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 14, 2026, 9:04 AM EDT
Completed Not applicable Interventional

Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19

NCT04412330
View directory record Official record
Conditions
Covid-19, Critical Illness, Post Intensive Care Unit Syndrome, Muscle Weakness
Interventions
ICU Recovery + Physical Therapy
Other
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 14, 2026, 9:04 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study

NCT04964154
View directory record Official record
Conditions
Covid19 Virus Infection
Interventions
Protect Your Elders Campaign
Behavioral
Lead sponsor
North Carolina Central University
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pembroke, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 14, 2026, 9:04 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

NCT04415073
View directory record Official record
Conditions
Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome
Interventions
SNDX-6352, Placebo
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Scottsdale, Arizona • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 14, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957
View directory record Official record
Conditions
COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury, Acute Respiratory Distress Syndrome
Interventions
LSALT peptide, Placebo
Drug
Lead sponsor
Arch Biopartners Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 14, 2026, 9:04 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Dysbiosis & Long COVID

NCT06825819
View directory record Official record
Conditions
COVID-19
Interventions
Subjects with and without Long COVID
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 14, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

NCT05289037
View directory record Official record
Conditions
COVID-19
Interventions
AS03, BNT162b2, BNT162b2 (B.1.1.529), BNT162b2 (B.1.351), BNT162b2 bivalent (wildtype and Omicron BA.1), BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5), CoV2 preS dTM [B.1.351], CoV2 preS dTM/D614, CoV2 preS dTM/D614+B.1.351, mRNA-1273, mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, Sodium Chloride, 0.9%
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 14, 2026, 9:04 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 14, 2026, 9:04 AM EDT
Completed Not applicable Interventional

A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests

NCT04568356
View directory record Official record
Conditions
SARS CoV-2
Interventions
Direct Antigen Tests for COVID-19
Diagnostic Test
Lead sponsor
E25Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 14, 2026, 9:04 AM EDT
Terminated Phase 2 Interventional Results available

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

NCT04470622
View directory record Official record
Conditions
COVID-19
Interventions
Aprepitant injectable emulsion, Saline Placebo
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Sheffield, Alabama • Orange, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 14, 2026, 9:04 AM EDT
Withdrawn Phase 2 Interventional

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

NCT05545319
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cooperstown, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 14, 2026, 9:04 AM EDT